HOME >> BIOLOGY >> NEWS
Einstein's Dr. Vern Schramm elected to the National Academy of Sciences

May 1, 2007 (BRONX, NY) -- Vern L. Schramm, Ph.D., Professor and Ruth Merns Chair of Biochemistry at the Albert Einstein College of Medicine of Yeshiva University, has been elected to the National Academy of Sciences, the nations most prestigious honorary society for scientists. His election was announced today at the Academys annual meeting in Washington, D.C.

Dr. Schramm has been a member of the Einstein faculty since 1987. Throughout his career, he has carried out groundbreaking research into the mechanisms involved in enzymatic reactions. This work has led to promising drugs now being tested in clinical trials for treating autoimmune diseases and several types of cancer.

Dr. Schramm studies the transition-state structure of enzyme-catalyzed reactions the shapes that reacting molecules assume when enzymes catalyze chemical reactions. As he describes it, Enzymes govern virtually all of the chemical transformations necessary for biological life but can also influence cells to become cancerous. By knowing the transition-state structure of enzyme-catalyzed reactions, we can design powerful inhibitors that can block those enzymes from acting and thereby treat or prevent cancer and other diseases.

One such inhibitor that Dr. Schramm has designed, known as Immucillin-H, is a promising anticancer agent for treating T-cell malignancies. It is currently in a pivotal phase IIb clinical trial (specifically targeted to study efficacy) at sites in the U.S., eastern and western Europe, and South America.

Another transition-state inhibitor developed by Dr. Schramm is now being studied as a possible treatment for autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disorders and for preventing the rejection of transplanted organs.

The election to the Academy is the latest among numerous honors recognizing Dr. Schramms many contributions in more than 35 years as a biochemistr
'"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
4-May-2007


Page: 1 2

Related biology news :

1. Einsteins Dr. E. Richard Stanley receives 2006 E. Donnall Thomas Prize
2. Einsteins Susan Band Horwitz, PhD wins Bristol-Myers Squibb Cancer Research Award
3. Candidate research sites selected for the National Ecological Observatory Network
4. Depiction of findings selected as 2007 Image of the Year by Society for Nuclear Medicine
5. CSHL selected for odENCODE Data Coordination Center
6. University of Arizona neurobiologist John Hildebrand elected to the National Academy of Sciences
7. 5 Stanford professors elected to National Academy of Sciences
8. Salk scientist Ursula Bellugi elected to National Academy of Sciences
9. Psychology professor elected to American Academy of Arts and Sciences
10. ORNLs Thundat elected fellow of AAAS
11. Leading scientists elected to EMBO ranks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/14/2019)... ... January 14, 2019 , ... CellMax ... cancer cells in blood, will present new findings at the ASCO Gastrointestinal Cancer ... colorectal cancer. The results from this study show CellMax Life’s blood test, based ...
(Date:1/10/2019)... (PRWEB) , ... January 09, 2019 , ... Dr. Beanlands ... Heart Institute in Ottawa, Ontario, Canada. He is also Director of its National ... of Medicine, in the Department of Radiology, and in the Department of Cellular and ...
(Date:1/10/2019)... ... 2019 , ... A major goal for pharmaceutical companies has ... significantly more expensive in vivo studies in order to reduce costs and improve ... researchers have begun to adopt 3D cell culture models which have been shown ...
Breaking Biology News(10 mins):
(Date:12/20/2018)... ... December 20, 2018 , ... New Year’s brings reflection ... changes in regulations in the European Union (EU) on the horizon, Jim Kasic, president ... , “The transition to the EU Medical Device Regulation (MDR), digital health, and big ...
(Date:12/18/2018)... ... December 18, 2018 , ... Patients with early stages of breast cancer who ... post-treatment versus whole breast irradiation, a new study suggests. , Patients with early stage ... irradiation after removal of the cancerous tumor because there is a 30 to 40 ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial Discovery Group LLC (MDG) ... been part of their strategic plan and an important milestone in increasing their ... opportunities for MDG within the $44 Billion human probiotic market. This plan is ...
(Date:12/5/2018)... (PRWEB) , ... December 04, ... ... an established North American full-service contract research organization (CRO), announced the acquisition ... transaction significantly strengthens ARG’s reach and experience in the management of clinical ...
Breaking Biology Technology:
Cached News: